antibody level – Page 4 – Communicable Diseases Research

Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study

CoronaVac, BNT162b2, ChAdOx1 COVID-19 백신 및 단일 추가 접종 후 SARS-CoV-2 anti-spike 수용체 결합 도메인 IgG 항체 반응의 비교: 전향적, 종단적 인구 기반 연구

Article

Published on 2022-04-012022-09-12
Journal: The Lancet. Microbe [Category] COVID19(2023년), MERS, SARS, 진단,

SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 – April 2021

응급실 의료 종사자 집단의 SARS COV-2 항뉴클레오캡시드 및 항스파이크 항체: 2020년 9월 - 2021년 4월

Article

Published on 2022-04-012022-09-11
Journal: The American journal of emergency medicine [Category] COVID19(2023년), MERS, SARS, 진단, 치료법,

[키워드] 95% CI age anti-spike antibodies anti-spike antibody antibody antibody level antibody levels Antibody Response Antigen baseline BNT162b2 Breakthrough infection breakthrough infections conducted Course COVID-19 infection decrease described emergency department examined Factor Healthcare system healthcare worker IgG antibodies IgG antibody immunogenicity incidence Infection mRNA mRNA-1273 nucleocapsid nucleocapsid antigen participant positive predictor prospective cohort study reduced SARS-CoV-2 SARS-CoV-2 antibodies SARS-COV-2 infection SARS-CoV-2 nucleocapsid SARS-CoV-2 spike antigen seronegative participant strained tested the antibody response the SARS-CoV-2 threshold vaccination Vaccine Vaccine immunogenicitiy. were measured
[DOI] 10.1016/j.ajem.2022.01.055 PMC 바로가기 [Article Type] Article

Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021

오스트리아 티롤에서 항 SARS-CoV-2 IgG 항체의 혈청유병률, 감소 및 상관관계: 2020년 6월에서 2021년 9월 사이에 수행된 35,193명의 헌혈자에 대한 대규모 연구

Article

Published on 2022-03-092022-09-11
Journal: Viruses [Category] MERS, SARS, 진단, 치료법,

Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine

Immunology

Published on 2022-01-312022-11-01
Journal: Frontiers in Immunology [Category] COVID-19,

[키워드] acute respiratory syndrome age Analysis analyzed antibody antibody level Antibody titer blood sample BNT162b2 mRNA BNT162b2 mRNA vaccine body mass index booster vaccination Characteristics Comorbidity coronavirus coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccine dose effective Effectiveness enrolled evaluate examined females first vaccination had no healthcare personnel healthcare worker interquartile range IQR Korea median Month NAb neutralizing antibody no evidence of objective participant performed positive prospective observational study Quantitative response Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 neutralizing antibody second second vaccination single center South Korea subject the antibody response university vaccination Vaccine waned were measured while worker
[DOI] 10.3389/fimmu.2022.827306 PMC 바로가기 [Article Type] Immunology

Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose

Article

Published on 2022-01-202022-10-28
Journal: Vaccines [Category] COVID-19,

Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination

COVID-19 감염 또는 예방 접종 후의 혈청 유병률 및 IgG 항체 수준

Article

Published on 2022-01-012022-09-12
Journal: Infectious diseases (London, England) [Category] 진단,

Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations

Article

Published on 2022-01-012022-10-06
Journal: JAMA Oncology [Category] Fulltext, SARS, 진단, 치료기술, 치료제,

[키워드] age anti-S anti-S antibody anti-SARS-CoV-2 anti-SARS-CoV-2 antibody antibody antibody level Cancer Chemotherapy cohort study cohorts cohorts of patient collected Combination Community control group determine develop disease dose first vaccination HCW HCWs Health care worker hematological highest hospital immunization immunocompromised individuals Immunotherapy independent Infection knowledge Lower lowest malignant tumor median men nucleocapsid outcome Patient Patients with cancer Protein Received response retrospective cohort study SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination Seroconversion serum sample solid tumor subgroup suggested therapy Total treated Treatment vaccination were measured women worker
[DOI] 10.1001/jamaoncol.2021.5437 PMC 바로가기 [Article Type] Article

Quantitative Analysis of SARS-CoV-2 Antibody Status between Patients with Cancer and Healthy Individuals with Extended Vaccination Dosing Intervals in Canada

캐나다에서 연장된 백신 접종 간격을 가진 암 환자와 건강한 개인 간의 SARS-CoV-2 항체 상태의 정량적 분석

Article

Published on 2021-12-242022-09-12
Journal: Current Oncology [Category] SARS, 진단,

[키워드] Analysis Anti-spike antibody antibody level AZD1222 binding antibody BNT162b2 Canada Cancer cancer patient Cancer patients Chemotherapy control group cross-sectional demonstrated domain dose Dosing ELISA enrolled enzyme-linked immunosorbent evaluate Extended group healthy hematological Hematological malignancy Humoral immunity IgG antibody individual interval knowledge mRNA-1273 Observed oncology participant Patient Protein response responses SARS-CoV-2 SARS-CoV-2 vaccine second dose serological serum significantly lower solid cancer solid cancer patients status the antibody response the healthy the mean the patient the SARS-CoV-2 therapy Treatment vaccination Vaccine
[DOI] 10.3390/curroncol29010006 PMC 바로가기 [Article Type] Article

Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity

BNT162b2 SARS-CoV-2 백신 유도 면역의 알파 및 베타 변이체에 대한 중화의 연령 의존적 감소

Research Article

Published on 2021-12-012022-09-10
Journal: Microbiology Spectrum [Category] SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 age All participants anti-RBD antibody antibody level antibody levels Antibody test Antigen basic Beta binding domain BNT162b2 BNT162b2 vaccine Clinical characteristics collected Coronavirus-2 correlated Cutoff decrease female groups Health care Health care worker health care workers heterogeneity high risk higher risk Humoral immunity Immunity include individual Infection interquartile range introduced IQR median mRNA vaccine mRNA vaccines neutralization Neutralizing Neutralizing activity Neutralizing antibodies of BNT162b2 Older age participant Patient patient age positive Pseudotyped virus questionnaire Questionnaires Randomly Receptor-binding domain reduction respiratory SARS-CoV-2 SARS-COV-2 infection second dose selected sera serum dilution Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Spike protein Toyama U/mL university vaccination variant variants Viral viral variant Viral variants virus viruses was obtained were measured wild type wild-type wild-type SARS-CoV-2 wild-type virus
[DOI] 10.1128/Spectrum.00561-21 PMC 바로가기 [Article Type] Research Article

Measurement of SARS-CoV-2-Specific Humoral and Cellular Immunity in Coronavirus Disease 2019 Convalescent Health Care Workers in Iraq

코로나바이러스 질병 2019 이라크의 회복기 의료 종사자의 SARS-CoV-2 특정 체액 및 세포 면역 측정

Article

Published on 2021-11-302022-09-12
Journal: Archives of Razi Institute [Category] MERS, SARS, 진단,

[키워드] acute respiratory syndrome adaptive addition Anti-RBD IgG antibody level binding domain Cell-mediated immunity conducted convalescent convalescent individual coronavirus coronavirus disease Coronavirus disease 2019 (COVID-19) COVID-19 disease severity eight enrolled enzyme-linked immunosorbent evaluated global pandemic HCW Health care worker humoral immune response Humoral immunity IgG antibody Immunity increase in Iraq knowledge lymphocyte measurement Mild moderate MTT proliferation quartile RBD Reinfection respiratory reveal robust S1 protein SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severe COVID-19 Symptom symptomatic the Coronaviridae the median time interval virus worker
[DOI] 10.22092/ari.2021.356135.1785 PMC 바로가기 [Article Type] Article